The National Institutes of Health on May 3 announced a new pilot program between the National Center for Advancing Translational Sciences and three major pharmaceutical companies in order to advance drug development.
Pfizer Inc., AstraZeneca and Eli Lilly have agreed to give academic researchers access to 20 compounds that passed through safety studies but didn’t make it beyond midstage clinical trials. The program utilizes the idea of “crowdsourcing” in the hope that outside researchers will be able to develop new uses for the abandoned therapeutic compounds.
Investigators also will have access to data related to the compounds to develop new grant proposals. NCATS has set aside $20 million to support grants for the program. The notice of intent to publish a request for applications has been released, and the first round of pre-applications will be due by mid-July.
The NIH also has released a request for information asking for input from the research community on the partnership program.
Read more about the partnership program in the ASBMB Today online exclusive article.